Biogen Inc vs Five Below Inc — how do they compare? Biogen Inc trades at $191.9 (market cap $30.86B), while Five Below Inc trades at $190 (market cap $10.59B). The key difference: Biogen Inc is far larger — about 2.9× Five Below Inc's market cap, and Biogen Inc is trading nearer its 52-week high, Five Below Inc nearer its low. Which is the better fit depends on your goals.
| BIIB | FIVE | |
|---|---|---|
Market Cap | $30.86B | $10.59B |
Sector | Health | Consumer Staples |
52-Week High | $216.63 | $247.71 |
52-Week Low | $122.68 | $131.94 |
Enterprise Value | $33.14B | $11.48B |
Trailing returns across standard periods
Latest headlines on both assets
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →Five Below is a value-oriented retailer that operated 1,190 stores in the United States as of the end of fiscal 2021. Catering to teen and preteen consumers, stores feature a wide variety of merchandise, the vast majority of which is priced below $6. The assortment focuses on discretionary items in several categories, particularly leisure (such as sporting goods, toys, and electronics
Read more on FIVE →